-
Logout
Enabling Precision Medicine: Launch of PD-L1 and HER2 Primary Antibodies for Cancer Research
Leica Biosystems is pleased to announce the launch of two new primary antibodies, PD-L1 and HER2, developed to support cancer research and therapy development. These antibodies, widely used in studying breast, lung, and other cancers, underscore our commitment to empowering pharmaceutical partners with high-quality assays.
This milestone reflects the capabilities of our newly established Center for Enabling Precision Medicine (CEPM). Designed to foster collaboration with pharmaceutical and academic partners, the CEPM streamlines the development and delivery of immunohistochemistry assays for cancer research and diagnostics. By situating our new R&D alongside manufacturing on the same campus, we’ve enhanced our ability to offer partners the quality, consistency, and scale needed to advance their research and development efforts
Our long-term partnerships are built on trust and a commitment to quality. As therapies progress from early discovery to clinical trials and regulatory approval, our partners depend on research and diagnostic tools that deliver consistent, reproducible results. Leveraging decades of expertise, Leica Biosystems provides assays with the precision and quality necessary to ensure reliable outcomes at every stage of therapy development.
“We’re proud of the early progress our teams have made, and the efficiencies realized through the integration of our R&D and manufacturing facilities,” said Karan Arora, Senior Vice President of Advanced Assays & Pharma Services. “This alignment allows us to quickly deliver assays that meet the rigorous quality standards our pharmaceutical and academic partners require.”
With this expansion of our portfolio, Leica Biosystems is committed to being a trusted partner for pharmaceutical and academic partners in developing precision diagnostics. We are dedicated to translating discoveries into diagnostics that improve lives.
Learn More
Explore how our new PD-L1 and HER2 antibodies can enhance your research and development:
About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As one of the only companies to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture.
